Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis : a clinicopathological study of 1,139 cases with long-term follow-up
The incidence of papillary thyroid carcinoma (PTC) is increasing worldwide. The biomarkers to identify aggressive types of PTC are limited, illustrating the need to establish reliable novel biomarkers. Protein disulfide isomerase A3 (PDIA3) is a chaperone protein that modulates the folding of newly synthesized glycoproteins and stress-responsive proteins in the endoplasmic reticulum. Although the role of PDIA3 in various cancers such as breast, uterine cervix, head and neck, and gastrointestinal tract has been examined, its expression in thyroid cancer has not been reported. We retrospectively reviewed accumulated data with long-term follow-up of 1,139 PTC patients, and investigated the correlation between immunohistochemical expression of PDIA3 in PTC patients and clinicopathological features and prognosis. PDIA3 expression was significantly lower in PTCs compared to normal thyroid tissues (NTT; n = 80, p = 0.002). In PTCs, correlation between low PDIA3 expression and lymph node metastasis (p = 0.018) and the number of positive nodes (p = 0.004) was observed. Patients with low PDIA3 expression exhibited worse cause-specific survival compared to those with high PDIA3 expression (p = 0.013). Our findings indicate that low PDIA3 expression is related to poor clinical outcome in PTC patients, and that PDIA3 may potentially be a novel ancillary biomarker. Further clarification of the biological role of PDIA3 in PTC is warranted for the future clinical application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Endocrine journal - 69(2022), 3 vom: 28. März, Seite 273-281 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kure, Shoko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1507/endocrj.EJ21-0394 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332707229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332707229 | ||
| 003 | DE-627 | ||
| 005 | 20231225220121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1507/endocrj.EJ21-0394 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332707229 | ||
| 035 | |a (NLM)34732604 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kure, Shoko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis |b a clinicopathological study of 1,139 cases with long-term follow-up |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The incidence of papillary thyroid carcinoma (PTC) is increasing worldwide. The biomarkers to identify aggressive types of PTC are limited, illustrating the need to establish reliable novel biomarkers. Protein disulfide isomerase A3 (PDIA3) is a chaperone protein that modulates the folding of newly synthesized glycoproteins and stress-responsive proteins in the endoplasmic reticulum. Although the role of PDIA3 in various cancers such as breast, uterine cervix, head and neck, and gastrointestinal tract has been examined, its expression in thyroid cancer has not been reported. We retrospectively reviewed accumulated data with long-term follow-up of 1,139 PTC patients, and investigated the correlation between immunohistochemical expression of PDIA3 in PTC patients and clinicopathological features and prognosis. PDIA3 expression was significantly lower in PTCs compared to normal thyroid tissues (NTT; n = 80, p = 0.002). In PTCs, correlation between low PDIA3 expression and lymph node metastasis (p = 0.018) and the number of positive nodes (p = 0.004) was observed. Patients with low PDIA3 expression exhibited worse cause-specific survival compared to those with high PDIA3 expression (p = 0.013). Our findings indicate that low PDIA3 expression is related to poor clinical outcome in PTC patients, and that PDIA3 may potentially be a novel ancillary biomarker. Further clarification of the biological role of PDIA3 in PTC is warranted for the future clinical application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunohistochemistry | |
| 650 | 4 | |a Lymph node metastasis (LNM) | |
| 650 | 4 | |a Papillary thyroid carcinoma (PTC) | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Protein disulfide isomerase A3 (PDIA3) | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Protein Disulfide-Isomerases |2 NLM | |
| 650 | 7 | |a EC 5.3.4.1 |2 NLM | |
| 700 | 1 | |a Chiba, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ebina, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Toda, Kazuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Jikuzono, Tomoo |e verfasserin |4 aut | |
| 700 | 1 | |a Motoda, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Mitani, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Sugitani, Iwao |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Kengo |e verfasserin |4 aut | |
| 700 | 1 | |a Ohashi, Ryuji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine journal |d 1993 |g 69(2022), 3 vom: 28. März, Seite 273-281 |w (DE-627)NLM074989081 |x 1348-4540 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2022 |g number:3 |g day:28 |g month:03 |g pages:273-281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1507/endocrj.EJ21-0394 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2022 |e 3 |b 28 |c 03 |h 273-281 | ||